|
|
|
|
|
|
|
25.11.25 - 22:03
|
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results (Business Wire)
|
|
|
- Conference Call and Webcast Today, November 25, 2025, at 4:30 p.m. ET
PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results.
“The recent FDA approval of REDEMPLO, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), is a transformational milestone for Arrowhead. REDEMPLO is the first and only FDA-approved siRNA medicine for people living with FCS and represents the first FDA-approval for a medicine leveraging Arrowhead's proprietary and differentiated Targeted RNAi Molecule (TRiM™) platform,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. “However, Arrowhead is truly just getting started and we are well positioned to execute on our aggressive goals in discovery, clinical development, business dev...
|
|
|
|
|
|
|
|
|
|
|
|
|
06.11.25 - 22:36
|
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results (Business Wire)
|
|
|
PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its financial results for the 2025 fiscal year ended September 30, 2025.
Webcast and Conference Call Details
Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.
For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI2700430252ab408a89dff83808477869. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistr...
|
|
|
28.10.25 - 21:33
|
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
|
|
|
PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 24, 2025, the Company's Board of Directors approved “inducement” grants to 84 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 127,230 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and vest annually over four years.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting...
|
|
|
|
|
|
|
|
|
|
|
|
|
04.09.25 - 14:15
|
Arrowhead Pharmaceuticals vor FDA-Entscheidung: Attraktive Kaufchance? (Sharedeals)
|
|
|
Arrowhead Pharmaceuticals steht kurz vor entscheidenden Weichenstellungen, die den langfristigen Erfolg des Unternehmens maßgeblich beeinflussen könnten. Rückenwind gibt's aktuell durch einen starken Pharma-Deal mit Novartis. Mit einem vielversprechenden Wirkstoffkandidaten, der kurz vor einer möglichen Zulassung durch die US-Arzneimittelbehörde FDA steht, sowie einer Reihe weiterer laufender Studien, befindet sich Arrowhead in einer entscheidenden Phase. Gleichzeitig eröffnet […]
The post Arrowhead Pharmaceuticals vor FDA-Entscheidung: Attraktive Kaufchance? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
